Intuitive Surgical Price Target Adjusted by Evercore ISI
Evercore ISI has raised its price target for shares of Intuitive Surgical (NASDAQ: ISRG) to $490, marking an increase from the previous target of $475, while maintaining an In Line rating. The firm’s assessment comes after Intuitive Surgical announced a remarkable year-over-year revenue growth of about 17%, which slightly beat market expectations.
Systems Revenue and Market Performance
The report highlighted that revenue from systems grew by 4%, while consumables revenue saw an increase of approximately 1.8%. A total of around 379 systems were placed in the quarter, which exceeded Street estimates by 12%, mainly due to an impressive performance in the U.S. market where placements surpassed expectations by 37%. However, the performance was less robust outside the U.S., particularly in European and Chinese markets. The quarter also saw a rise in the placement of da Vinci 5 (dV5) systems, increasing from 70 to 110 units.
Procedural Growth Insights
Procedural growth for Intuitive Surgical also topped expectations, showing an overall increase of roughly 18%. This figure, while impressive, included an additional day in the reporting period. Adjusting for this anomaly, the actual growth rate in procedures was about 17%. General surgery demand drove the majority of the growth, while bariatric procedures experienced a slight mid-single-digit decline. On the upside, Ion procedures boasted a remarkable growth rate exceeding 70%.
Financial Management and Guidance
The company exhibited strong operational leverage, with selling, general, and administrative expenses coming in approximately 130 basis points lower than anticipated. This management efficiency contributed to an increase in the operating margin. Earnings per share surged by around 26%, of which 20% was a result of higher revenue and improved operating margins, with the rest driven by increased interest income and a favorable lower tax rate.
Future Projections and Developments
Management has provided updated guidance, projecting procedure growth between 16% and 17%, while also lowering the anticipated growth in operating expenses to 10%-12%. They reiterated plans for a gradual rollout of the dV5 system, expecting to reach full ramp-up by mid-2025, though anticipating that depreciation expenses could impact operating margins in fiscal year 2025.
Valuation Changes and Market Comparisons
The valuation segment noted that Intuitive Surgical's price-to-earnings (P/E) ratio has expanded significantly since pre-pandemic times, especially compared to the more modest growth of the S&P 500. Both revenue and procedural growth have remained consistent, yet operating margins have outperformed previous expectations.
Analyst Updates and Market Reactions
Following this analysis, Evercore ISI raised its fiscal year 2025 earnings per share estimate by around 3%. The new price target of $490 indicates a P/E multiple of approximately 70 times when factoring in stock-based compensation.
Additional adjustments from financial institutions have also been noted, with Baird raising its price target to $565 and maintaining an Outperform rating. Wells Fargo reiterated its Overweight rating alongside a price target of $466, while BTIG continued with its Buy rating and a $494 target based on positive growth potential in the general surgery segment.
Recent Achievements and Leadership Changes
RBC Capital Markets additionally increased its target for Intuitive Surgical to $515, emphasizing strong acceptance of the latest dV5 robot among medical professionals. Redburn-Atlantic made an upgrade from Neutral to Buy with a new target of $510, reflecting a bright financial outlook.
These positive developments come in the wake of Intuitive Surgical's robust earnings and revenue metrics, including a 17% surge in global procedural volume and the placement of 70 da Vinci surgical systems. The company also recently announced a significant leadership transition with President David J. Rosa joining the Board of Directors.
Frequently Asked Questions
What recent changes did Evercore ISI make to Intuitive Surgical's stock rating?
Evercore ISI raised the stock price target to $490 while maintaining an In Line rating.
How has Intuitive Surgical performed in terms of revenue growth?
The company reported a year-over-year revenue growth of approximately 17%.
What factors contributed to Intuitive Surgical's operational efficiency?
Lower than expected selling, general, and administrative expenses contributed to improved operational leverage.
What is the projected procedure growth for Intuitive Surgical?
Management anticipates procedure growth between 16% and 17% for the upcoming fiscal period.
Which firms have recently altered their price targets for Intuitive Surgical?
Baird, Wells Fargo, BTIG, and RBC Capital Markets have made notable adjustments to Intuitive Surgical's price targets.
